Loading...

We've got a brand new version of Simply Wall St! Try it out

Ascent Industries

CNSX:ASNT
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ASNT
CNSX
CA$32M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Ascent Industries Corp., through its wholly-owned subsidiaries, engages in the cultivation, processing, production, development, and distribution of cannabis and cannabis-based products. The last earnings update was 258 days ago. More info.


Add to Portfolio Compare Print
ASNT Share Price and Events
7 Day Returns
0%
CNSX:ASNT
-0.8%
CA Pharmaceuticals
0.1%
CA Market
1 Year Returns
-
CNSX:ASNT
3.5%
CA Pharmaceuticals
-2.8%
CA Market
ASNT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ascent Industries (ASNT) 0% 0% 0% - - -
CA Pharmaceuticals -0.8% -8.7% -12.6% 3.5% 646.7% 464%
CA Market 0.1% -0.8% -0.3% -2.8% 11.4% 0.8%
1 Year Return vs Industry and Market
  • No trading data on ASNT.
  • No trading data on ASNT.
Price Volatility
Industry
5yr Volatility vs Market

ASNT Value

 Is Ascent Industries undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ascent Industries. This is due to cash flow or dividend data being unavailable. The share price is CA$0.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ascent Industries's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ascent Industries's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ASNT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-05-31) in CAD CA$-0.07
CNSX:ASNT Share Price ** CNSX (2019-03-15) in CAD CA$0.1
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 22.85x
Canada Market PE Ratio Median Figure of 545 Publicly-Listed Companies 14.96x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ascent Industries.

CNSX:ASNT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ASNT Share Price ÷ EPS (both in CAD)

= 0.1 ÷ -0.07

-1.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascent Industries is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Ascent Industries is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Ascent Industries's expected growth come at a high price?
Raw Data
CNSX:ASNT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.14x
Canada Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.13x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ascent Industries, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ascent Industries's assets?
Raw Data
CNSX:ASNT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-05-31) in CAD CA$0.10
CNSX:ASNT Share Price * CNSX (2019-03-15) in CAD CA$0.1
Canada Pharmaceuticals Industry PB Ratio Median Figure of 145 Publicly-Listed Pharmaceuticals Companies 2.72x
Canada Market PB Ratio Median Figure of 2,421 Publicly-Listed Companies 1.42x
CNSX:ASNT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ASNT Share Price ÷ Book Value per Share (both in CAD)

= 0.1 ÷ 0.10

0.99x

* Primary Listing of Ascent Industries.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ascent Industries is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Ascent Industries's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ascent Industries has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

ASNT Future Performance

 How is Ascent Industries expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ascent Industries has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
88.5%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ascent Industries expected to grow at an attractive rate?
  • Unable to compare Ascent Industries's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ascent Industries's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Ascent Industries's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ASNT Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 88.5%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 54.9%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14.4%
Canada Market Revenue Growth Rate Market Cap Weighted Average 6%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ASNT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ASNT Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-05-31 10 -10 -14
2018-02-28 11 -7 -10
2017-05-31 5 -2 -3
2016-05-31 1 -2 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ascent Industries is high growth as no earnings estimate data is available.
  • Unable to determine if Ascent Industries is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ASNT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 year ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ascent Industries Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ASNT Past Financials Data
Date (Data in CAD Millions) EPS *
2018-05-31 -0.07
2018-02-28 -0.05
2017-05-31 -0.02
2016-05-31 -0.02

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ascent Industries will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Ascent Industries's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  2. Ascent Industries's competitive advantages and company strategy can generally be found in its financial reports archived here.
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ascent Industries's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ascent Industries has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

ASNT Past Performance

  How has Ascent Industries performed over the past 5 years?

  • Ascent Industries's last earnings update was 258 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ascent Industries's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ascent Industries does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Ascent Industries's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ascent Industries's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ascent Industries's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ascent Industries Company Filings, last reported 1 year ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ASNT Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-05-31 9.92 -13.77 10.79 0.15
2018-02-28 10.97 -9.52 7.81 0.13
2017-05-31 4.88 -2.94 2.95 0.08
2016-05-31 0.68 -1.79 0.60 0.05
2015-05-31 -1.29 1.07 0.10

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ascent Industries has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ascent Industries has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ascent Industries improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ascent Industries's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ascent Industries has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

ASNT Health

 How is Ascent Industries's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ascent Industries's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ascent Industries is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ascent Industries's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ascent Industries's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ascent Industries Company Filings, last reported 1 year ago.

CNSX:ASNT Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-05-31 22.05 5.61 2.95
2018-02-28 20.33 5.63 5.27
2017-05-31 10.82 5.72 1.12
2016-05-31 4.58 1.79 0.41
2015-05-31
  • Ascent Industries's level of debt (25.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Ascent Industries's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ascent Industries has less than a year of cash runway based on current free cash flow.
  • Ascent Industries has less than a year of cash runway if free cash flow continues to grow at historical rates of 71.6% each year.
X
Financial health checks
We assess Ascent Industries's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ascent Industries has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

ASNT Dividends

 What is Ascent Industries's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ascent Industries dividends.
If you bought CA$2,000 of Ascent Industries shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ascent Industries's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ascent Industries's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ASNT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.7%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.6%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ascent Industries has not reported any payouts.
  • Unable to verify if Ascent Industries's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ascent Industries's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ascent Industries has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ascent Industries's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ascent Industries afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ascent Industries has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

ASNT Management

 What is the CEO of Ascent Industries's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Paul Dillman
AGE 58
TENURE AS CEO 0.2 years
CEO Bio

Mr. Paul R. Dillman Jr. is an Interim Chief Executive Officer and Director at Ascent Industries Corp. since April 26, 2019. Mr. Dillman served as an Executive Vice President of Global Sales and Marketing at Emerald Health Therapeutics, Inc. from October 11, 2018 to November 22, 2018. He was a Vice President of Sales & Marketing at Emerald Health Therapeutics, Inc. since 2018 to October 11, 2018. He served as the President, Secretary and Treasurer of Revenue.com Corporation from incorporation to completion of acquisition of Virurl in December 2014. Mr. Dillman has extensive experience as a General Manager and Senior Marketing Executive for companies ranging in size from start-up companies to global multi-national organizations. From June 2012 to November 2013, he served as the President of International for Electronic Cigarettes International Group, Ltd., where he was responsible for identifying distributors, establishing partnerships and generating sales globally, and also oversaw establishment of its Asian distribution centre. From August 2008 to May 2010, he was responsible for global marketing efforts across 100 airlines for DTI Software Inc., a provider of inflight media content to the airline industry. He has also served as Deputy Group Marketing Director for Pacific Group for The Coca-Cola Company, as a Vice President of Marketing & Sales and Global Brands for Anheuser-Busch InBev, a leading global brewer, and in various management positions with Altria Group, Inc. through its subsidiary, Philip Morris, one of the world's largest tobacco companies, and its former subsidiary, Kraft Foods. He has been a Director of Revenue.com Corporation since March 14, 2014. Since March 2010, he has been on the Board of Media City. Mr. Dillman obtained a Master of Science in Systems Management from the University of Southern California in 1984 and a Bachelor of Science in Nuclear Engineering from the United States Military Academy in 1981.

CEO Compensation
  • Insufficient data for Paul to compare compensation growth.
  • Insufficient data for Paul to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the Ascent Industries management team in years:

0.2
Average Tenure
  • The average tenure for the Ascent Industries management team is less than 2 years, this suggests a new team.
Management Team

Paul Dillman

TITLE
Interim CEO & Director
AGE
58
TENURE
0.2 yrs

Mark Lotz

TITLE
Interim CFO & Director
TENURE
0.2 yrs

Jonathan Bey

TITLE
Vice President of Investor Relation

Chris Lee

TITLE
Chief Marketing Officer
TENURE
2.4 yrs

Janet Joo

TITLE
Vice President of Human Resources
Board of Directors Tenure

Average tenure of the Ascent Industries board of directors in years:

0.2
Average Tenure
  • The average tenure for the Ascent Industries board of directors is less than 3 years, this suggests a new board.
Board of Directors

Paul Dillman

TITLE
Interim CEO & Director
AGE
58
TENURE
0.2 yrs

Mark Lotz

TITLE
Interim CFO & Director
TENURE
0.2 yrs

David Hurford

TITLE
Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
24. Feb 19 Sell Philip Campbell Individual 19. Feb 19 19. Feb 19 -26,564,735 CA$0.11 CA$-2,789,289
23. Feb 19 Sell James Poelzer Individual 19. Feb 19 19. Feb 19 -2,946,512 CA$0.11 CA$-309,383
23. Feb 19 Sell Philip Campbell Individual 19. Feb 19 19. Feb 19 -487,500 CA$0.11 CA$-51,187
23. Feb 19 Sell Reid Parr Individual 19. Feb 19 19. Feb 19 -26,956,506 CA$0.11 CA$-2,830,425
01. Oct 18 Sell Pacific Opportunity Capital Ltd, Asset management Arm Company 28. Sep 18 28. Sep 18 -35,000 CA$0.70 CA$-24,500
21. Aug 18 Buy Mark Brown Individual 20. Aug 18 20. Aug 18 50,000 CA$0.40 CA$19,750
13. Aug 18 Buy Mark Brown Individual 09. Aug 18 09. Aug 18 50,000 CA$0.48 CA$24,000
X
Management checks
We assess Ascent Industries's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ascent Industries has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

ASNT News

Simply Wall St News

ASNT Company Info

Description

Ascent Industries Corp., through its wholly-owned subsidiaries, engages in the cultivation, processing, production, development, and distribution of cannabis and cannabis-based products. It offers a product suite of approximately 40 products under various consumer-focused brands, including gel capsules, oils, tinctures, vaporizer pens, pre-rolled joints, edibles, concentrates, and dried cannabis flowers. The company is also involved in the cannabis-based research with Simon Fraser University to explore the therapeutic benefits of various cannabinoid formulations. Ascent Industries Corp. offers its products for the medical and adult-use markets in Canada and the United States. In addition, it intents develops a network of medical clinics and a digital portal across Canada that provides medical professionals and its product range. The company has a strategic alliance with Green Sage, LLC. Ascent Industries Corp. was founded in 2013 and is headquartered in Maple Ridge, Canada.

Details
Name: Ascent Industries Corp.
ASNT
Exchange: CNSX
Founded: 2013
CA$32,015,145
320,151,457
Website: http://www.ascentindustries.com
Address: Ascent Industries Corp.
Corporate 260,
22529 Lougheed Highway,
Maple Ridge,
British Columbia, V2X 0T5,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ASNT Common Shares Canadian National Stock Exchange CA CAD 09. Aug 2018
OTCPK PGTM.F Common Shares Pink Sheets LLC US USD 09. Aug 2018
Number of employees
Current staff
Staff numbers
0
Ascent Industries employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/13 01:28
End of day share price update: 2019/03/15 00:00
Last earnings filing: 2018/09/28
Last earnings reported: 2018/05/31
Last annual earnings reported: 2018/05/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.